• Target：
• Bcr

• Fields：
• >>Pathways in cancer;>>Chronic myeloid leukemia

• Gene Name：
• BCR

• Protein Name：
• Breakpoint cluster region protein

• Human Gene Id：
• 613

• Human Swiss Prot No：
• P11274

• Mouse Gene Id：
• 110279

• Mouse Swiss Prot No：
• Q6PAJ1

• Immunogen：
• The antiserum was produced against synthesized peptide derived from human Bcr around the phosphorylation site of Tyr360. AA range:331-380

• Specificity：
• Phospho-Bcr (Y360) Polyclonal Antibody detects endogenous levels of Bcr protein only when phosphorylated at Y360.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• WB 1:500 - 1:2000. IHC 1:100 - 1:300. IF 1:200 - 1:1000. ELISA: 1:40000. Not yet tested in other applications.

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• BCR;BCR1;D22S11;Breakpoint cluster region protein;Renal carcinoma antigen NY-REN-26

• Observed Band(KD)：
• 142kD

• Background：
• A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008],

• Function：
• catalytic activity:ATP + a protein = ADP + a phosphoprotein.,disease:A chromosomal aberration involving BCR is a cause of chronic myeloid leukemia (CML) [MIM:608232]. Translocation t(9;22)(q34;q11) with ABL1. The translocation produces a BCR-ABL found also in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).,domain:The DH domain is involved in interaction with CCPG1.,domain:The region involved in binding to ABL1 SH2-domain is rich in serine residues and needs to be Ser/Thr phosphorylated prior to SH2 binding. This region is essential for the activation of the ABL1 tyrosine kinase and transforming potential of the chimeric BCR-ABL oncogene.,function:GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity.,PTM:Autophosphorylated.,similarity:Contains 1 C2 domai

• Subcellular Location：
• Cell junction, synapse, postsynaptic density . Cell projection, dendritic spine . Cell projection, axon . Cell junction, synapse .

• Expression：
• Brain,Epithelium,Platelet,Renal cell carcinoma,T-cell,

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs